Anixa is harnessing the body's immune system in the fight against cancer.

By using the body’s immune system, Anixa Biosciences, Inc. is taking multiple approaches to fighting cancer—developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed.


We are developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body’s immune response to the presence of a malignancy.



We are developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer.

Breast Cancer Vaccine

We are developing a revolutionary breast cancer vaccine technology focused on treating as well as preventing triple negative breast cancer (TNBC), the most lethal form of the disease.

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus

Latest News & Events

Anixa Biosciences Announces Presentation at AI and Big Data in Cancer Conference


Anixa Biosciences and Moffitt Cancer Center Announce Completion of Viral Vector Reformulation for CAR-T Program


Anixa Biosciences Announces Presentation at AACR Liquid Biopsies Conference


Stock Data

View Investors Relations
Nasdaq: ANIX

Cancer of the Lung, Breast, Colon, Prostate, and Stomach are the five most prevalent cancers worldwide.